Navigation Links
Early treatment of systemic onset JIA with anakinra restores the IL-18 response
Date:6/12/2009

Copenhagen, Denmark, Friday 12 June 2009: First line treatment with anakinra (an interleukin-1 (IL-1) receptor antagonist), results in a 'good' clinical response (ACRp90) in patients newly diagnosed with systemic onset juvenile idiopathic arthritis (SoJIA), and restores the deficient IL-18 response of natural killer (NK) cells*, according to a new study presented today at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.

During the six month study, numbers of NK cells slightly increased initially but remained stable throughout treatment with anakinra, although specific lysis (the death of a cell by breaking of the cellular membrane) was restored to normal within just three days. Interestingly, the NK cell response after IL-18 stimulation was restored and sustained at normal levels, as seen in healthy children, during the follow up period suggesting that anakinra was able to mediate levels of cells involved in the immune response.

JIA is the most common form of persistent arthritis in children under the age of 16 years. It differs significantly from arthritis commonly seen in adults (such as osteoarthritis and rheumatoid arthritis) as, in addition to inflammation of the joints, there may also be inflammation of the eyes and internal organs, as well as skin rash (exanthema) and fever. Children with SoJIA, a subtype of JIA, are known to have defective NK cell function which compromises their immune systems, since NK cells (a type of cytotoxic lymphocyte, or white blood cell, that is capable of killing infected cells) play a major role in the rejection of cells infected by viruses and malfunctioning cell types including those commonly found in tumours.

Dr Wilco de Jager of the University Medical Centre Utrecht, The Netherlands, who led the study, said: "In patients with SoJIA, the essential cell-based regulatory systems that make up cell based immunity are impaired. Our study has shown that, once NK cell levels and function are restored to normal, the cytokine pathway specifically involving IL-18 is restored, which elicited a good clinical response in this patient group. The underlying processes involved in auto inflammatory diseases are complex and these results suggest a potential new treatment strategy for children with newly-diagnosed SoJIA."

Researchers in this study recruited ten children with newly-diagnosed SoJIA, initiating treatment with anakinra prior to steroids. During a six month follow-up period, absolute NK cell numbers and function, cytokine profiles, and NK cell response after IL-18 stimulation, were monitored.

Following treatment, clinical parameters such as fever, exanthema and arthritis resolved after 3 days. A rapid decrease in ESR (erythrocyte sediment rate; an indication of inflammation), CRP (C reactive protein; a marker for inflammation), ferritin (a test of iron stores in the body) and sIL-2R (soluble interleukin 2 receptor) was observed. No differences of IL-1alpha, IL-1beta and IL-33 were observed, but levels of IL-6, IL-1RA and IL-18 returned to normal, as observed in healthy controls. During follow-up, two patients flared following anakinra treatment.

*NK cells are a type of cytotoxic lymphocyte that constitute a major component of the innate immune system. NK cells play a major role in the rejection of tumors and cells infected by viruses. The cells kill by releasing small cytoplasmic granules of proteins called perforin and granzyme that cause the target cell to die by apoptosis or necrosis.


'/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Pot bellies linked to early signs of cardiovascular disease
2. Eye-staining technique offers early detection for dry eye syndrome
3. Early Weight Loss in Women Linked to Dementia
4. Isolation of a new gene family essential for early development
5. U of M study: Early treatment can reverse heart damage
6. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Pop stars more than twice as likely to die an early death
9. Exercise and yoga improves quality of life in women with early-stage breast cancer
10. Research says doctors gender may hinder early diagnosis of heart disease in women
11. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... ... not your typical author. She went from working as a movie extra on Bill Murray’s ... she isn’t swimming as a performing mermaid. , Her book isn’t typical either. In Carothers’ ... comedic look at the dysfunctions of God’s family, before Lucifer was sent to hell. ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail ... addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , ... had 800 customers and 2,250 RCEs at the time of acquisition. In the ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim ... over nerve agents and the deadly use of chemical weapons. Many questions exist about ... even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is ... Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads ... founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the ...
(Date:2/25/2017)... ... ... FCPX users now have the ability to sharpen a desired color range ... have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, and ... can visually see the color range effected with ease all within Final Cut ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a ... diagnostic tests and pathology services, announced today the acceptance ... United States and Canadian Academy ... in San Antonio, Texas . ... from the Company,s extensive experience in molecular thyroid testing, ...
(Date:2/27/2017)... 27, 2017  International Biophysics Corporation, a global medical device ... announced a 34% revenue growth in 2016 when compared to ... sales.  This growth was fueled by its AffloVest® sales in ... the expansion of its global sales of surgical product lines. ... "As we enter our 25 th year in delivering ...
(Date:2/27/2017)... 2017   Vitasome ® Labs , Inc. ... its groundbreaking new liposome technology. Whereas vitamins lose on ... digestion per Physician,s Desk Reference , Vitasome , ... nutritional waste and are scientifically formulated to: ... Improve bioavailability with a vastly higher absorption ...
Breaking Medicine Technology: